Changes in plasma potassium concentration after administration of depolarizing neuromuscular blockers were measured in patients during halothane-nitrous oxide anaesthesia. Suxamethonium 100 mg intravenously caused a peak rise of 0.55 m.equiv/1. and decamethonium 4 mg produced an elevation of similar magnitude. Injured patients had increases in potassium averaging 1.80 m.equiv/1. there being a direct correlation between degree of rise and time since injury. By giving tubocurarine 0.1 mg/kg body weight 5 minutes beforehand, the elevation in potassium caused by suxamethonium, though not by decamethonium, could be halved.
Although it has been known for years that plasma potassium rises after administration of depolarizing muscle relaxants (Paton, 1956) , the possible dangers of this have only recently been appreciated. The hyperkalaemia can be of sufficient degree to cause ventricular tachycardia and fibrillation, especially in the burned or injured patient (Lowenstein, 1966; Belin and Karleen, 1966; Tolmie, Joyce and Mitchell, 1967; Mazze and Dunbar, 1968) . In this study plasma potassium changes were measured after administration, during anaesthesia, of either suxamethonium or decamethonium to healthy individuals and to patients who had been injured. Since the potassium rise might account for arrhythmias in the digitalized person following suxamethonium administration (Dowdy and Fabian, 1963) , we also measured the plasma potassium changes in a group of digitalized patients. Finally because previous studies in animals have demonstrated that tubocurarine or gallamine, given before the depolarizing blocker, can minimize the expected hyperkalaemia (Klupp et al., 1954; Stevenson, 1960) , we examined this effect of tubocurarine in man.
METHODS
Plasma potassium levels were measured in three groups of adult patients, a total of 93 individuals. The 27 in the first group (Group 1) were fit patients who underwent induction of anaesthesia, tracheal intubation and subsequent operation.
Seventeen in the group received suxamethonium (100 mg or 40 mg intravenously) and 4 received tubocurarine (0.1 mg/kg intravenously) prior to intubation. The remaining 6 were intubated without relaxant. The second group (Group 2), 46 digitalized patients who were to undergo heart surgery, was divided into four sub-groups, depending on the relaxant(s) given before intubation. These were either suxamethonium (100 mg intravenously, 8 patients), decamethonium (4 mg intravenously, 12 patients) or tubocurarine (0.1 mg/kg body weight intravenously) followed 5 minutes later by the above doses of either suxamethonium (16 patients) or decamethonium (10 patients). The final group of 20 patients (Group 3) were individuals who had sustained trauma such as burns, open fractures and gunshot wounds 4-55 days before and who were now to have corrective operations. This group received either suxamethonium or tubocurarine and suxamethonium in the above doses and time sequence. Doses of relaxants as well as certain vital statistics are given in table I.
Patients were premedicated 60 minutes before induction with atropine and a barbiturate. Induction was usually accomplished with nitrous oxide, oxygen and halothane, although in a few instances thiopentone (75-200 mg) was used. Anaesthesia was maintained with nitrous oxide (1 l./min) with oxygen (1 l./min) in a semiclosed circle system along with halothane (0.5-1.5 per cent) added from a Copper Kettle. Respiration was controlled following induction and continued until blood sampling was completed. An arterial catheter was placed and sampling begun between 10 and 25 minutes after the onset of anaesthesia. Samples for potassium were drawn at 3 and 1 minutes before the injection of suxamethonium or decamethonium, and at 1, 3, 7, 15, 30 and 60 minutes afterwards. Tubocurarine was administered 2 minutes before the first blood sample was taken (5 minutes before the depolarizing blocker or before intubation when no further blocker was given). In the 6 patients not receiving relaxants sampling was begun 3 minutes before intubation.
During the sampling period, fluid administration was limited to 50 ml of 5 per cent dextrosewater and no additional relaxants or blood transfusions were given. The electrocardiogram was monitored in all patients throughout induction and the sampling period. Arterial blood gases, obtained in 6 patients during the sampling period, were within normal limits.
Blood specimens were placed in heparinized tubes and centrifuged within 5 minutes of collection. The potassium estimate was made with an Instrumentation Laboratories Flame Photometer, Model 143. A Fischer and Porter automatic dilutor was used to dilute 0.1 ml of the plasma or standard to 20 ml using 15 m.equiv/1. lithium in double-distilled water. Data represent the means of at least two readings on each of two aliquots of blood. The mean of the differences between 100 duplicate potassium determinations was 0.025 m.equiv/1. (SD 0.028). No haemolysis was noted in any samples.
Statistical comparisons were made using Student's t test. Significance was attached to a probability of 5 per cent or less. 
RESULTS
Results are displayed in tables II and III. In brief no significant change in plasma potassium concentration was found in patients not receiving muscle relaxants. On the other hand, there occurred a prompt and significant rise in plasma potassium after suxamethonium administration, peaking between 1 and 7 minutes. The 40-mg dose of suxamethonium was associated with a smaller and less prolonged elevation of plasma potassium when compared with the 100-mg dose. Though the elevation in potassium was greater in Group 1 than Group 2 for similar doses of suxamethonium, statistically the difference was insignificant. The peak level of potassium in the injured patients (Group 3) was approximately three times that of Group 1, a difference which was highly significant (P<0.01). Decamethonium administration was similarly associated with a rise in plasma potassium which, however, peaked later than that following suxamethonium. There was no significant difference between the increases in plasma potassium produced by suxamethonium and by decamethonium in Group 2 except at the 3-minute point (P<0.05).
Tubocurarine had a pronounced effect on the changes in plasma potassium associated with suxamethonium. In both Groups 2 and 3 the peak rise in potassium following administration of suxamethonium was significantly less (P<0.05) when tubocurarine had been given previously than when it had been omitted. By 15 minutes and beyond, though the potassium was still lower in tubocurarine pretreated patients, the difference was no longer significant. Tubocurarine did not abolish marked rises of potassium in all cases, for patient 19 in Group 3 received both tubocurarine and suxamethonium and had an increase of 2.81 m.equiv/1. This dose of tubocurarine had no effect on the potassium increase after decamethonium administration.
DISCUSSION
"Depolarization of excitable membranes generally leads to potassium loss from the cell concerned" (Paton, 1959) . In this study the cells are probably those of skeletal muscle. This perhaps best explains the rise in plasma potassium after decamethonium or suxamethonium administration. The transient hyperkalaemia has now been demonstrated in intact animals, in muscle preparations, and in man. The potassium rise has also been attributed to gross muscle fasciculation but this is unlikely in view of the elevation in potassium after decamethonium and after tubocurarine and suxamethonium when no fasciculations are seen. Another possible cause is sympathetic hyperactivity from suxamethonium (Galindo and David, 1962) although Paton's work in hepatectomized animals casts doubt on such a mechanism (Paton, 1956 ).
In any case there is a prompt hyperkalaemia following depolarizing muscular blockers, reaching a peak between 1 and 7 minutes after intravenous administration. This time for maximal rise in potassium correlates with the clinical examples of cardiac arrest occurring several minutes after suxamethonium administration. The effect of suxamethonium is similar in both digitalized and non-digitalized patients. Decamethonium, with its slower onset of paralysis, caused a peak rise in potassium later than did suxamethonium. The rise in potassium appears to be dose-related. In this study 40 mg of suxamethonium produced a smaller and more transient rise in potassium than did a 100-mg dose. Tolmie, Joyce and Mitchell (1967) found a dose response relation, too, in the patient whose case they reported.
That potassium rises to an even greater extent in injured patients has also been documented by other workers (Mazze and Dunbar, 1968; Strieker and Morrow, 1968) . The hyperkalaemia is more prompt as well, peaking within 3 minutes of administration. The reason for the greater rise with injury is not known but may be the result of cellular membrane trauma resulting in a greater loss or slower re-uptake of potassium by the cell. The rise in potassium does not seem to be related to the degree of trauma, at least in our 20 patients, but rather with the time interval between injury and giving suxamethonium. We found a highly significant correlation (P<0.01) between time since injury and increase in potassium (table III) . Lowenstein (1966) noted that the majority of cardiac arrests reported in burned patients receiving suxamethonium occurred between 21 and 56 days after injury. From our data one might expect the greatest increase in potassium to be in this time period.
The rise in potassium after suxamethonium can be diminished on the average by pretreatment with tubocurarine. With our dose schedule this resulted in about half the expected peak rise in both injured and uninjured patients. The mechanism for this is unknown. Tubocurarine does not itself lower plasma potassium as has been demonstrated by our study and by Strieker and Morrow (1968) who gave five times the dose of tubocurarine that we used. This absence of effect on plasma potassium by tubocurarine has also been demonstrated in dogs (Klupp et al., 1954) . Perhaps tubocurarine stabilizes the muscle cell membrane, preventing potassium loss. Why tubocurarine had no effect on decamethoniuminduced hyperkalaemia is also puzzling. 
